Who Paid My Doc
Matthew Krafft
Morgantown, WV Medical Doctor
NPI 1477965135 CMS profile 4221155
1 Medical Center Dr, Morgantown, WV 26506
General payments
$27,533
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Matthew Krafft of Morgantown, WV is reported in the CMS Open Payments database as having received $27,533 across 32 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $749 | 12 | |
| 2024 | General | $466 | 4 | |
| 2023 | General | $383 | 5 | |
| 2022 | General | $44 | 2 | |
| 2021 | General | $25,000 | 1 | |
| 2019 | General | $891 | 8 |
Beside peers
- Matthew Krafft
- West Virginia median
- Middle half of West Virginia
- National median
In program year 2025, general payments to Matthew Krafft were reported at $749. Among 5,795 West Virginia profiles paid that year, the median was $155 and the middle half received between $45 and $520.
Show as a table
| Year | Matthew Krafft | West Virginia median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $891 | $145 | $43–$559 | $163 |
| 2020 | $0 | $105 | $32–$362 | $114 |
| 2021 | $25,000 | $124 | $35–$430 | $132 |
| 2022 | $44 | $134 | $41–$475 | $149 |
| 2023 | $383 | $144 | $42–$508 | $160 |
| 2024 | $466 | $146 | $45–$531 | $164 |
| 2025 | $749 | $155 | $45–$520 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
135
Drug cost
$465,925
Branded share of claims
31.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Stelara Ustekinumab | Brand | 17 | $464,655 | |
| Omeprazole | Generic | 25 | $339 | |
| Pantoprazole Sodium | Generic | 24 | $310 | |
| Ondansetron Odt Ondansetron | Brand | 13 | $302 | |
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | Brand | 12 | $227 | |
| Promethazine Hcl | Generic | 12 | $63 | |
| Tramadol Hcl | Generic | 32 | $28 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 75 billing codesPaid by Medicare
$94,832
Medicare patients
375
Services billed
772
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 54% | |
| Ischemic heart disease | 45% | |
| Diabetes | 42% | |
| Depression | 39% | |
| COPD | 36% | |
| Chronic kidney disease | 33% | |
| Heart failure | 30% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
32 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.